

Research Article

CD4 cell counts recovery in HIV/TB co-infected patients in a tertiary care Hospital

Ketki Jangid*, Shalini Malhotra, Shiwangi Sharma, Charoo Hans

Department of Microbiology, PGIMER & Dr. Ram Manohar Lohia Hospital, Baba Kharak Singh Marg, New Delhi- 110001, India

***Corresponding author**

Dr. Ketki Jangid

Email: jangidketki@gmail.com

Abstract: Tuberculosis is a common opportunistic infection and a leading cause of death in HIV patients worldwide, especially in developing countries. The study was conducted to evaluate the relation of CD4 counts to occurrence and type of TB and to observe for the recovery of CD4 counts after treatment for tuberculosis in patients of pulmonary tuberculosis and extra pulmonary tuberculosis. This retrospective study was conducted for a period of 2 months (February 2015- March 2015) at Dr. Ram Manohar Lohia Hospital & PGIMER. Total Number of HIV positive patients that came for CD4 testing were 1187. 80 patients who had dual infection (HIV with tuberculosis) were included in the study. Details regarding age, sex, duration of HIV, ART therapy, type of tuberculosis whether PTB or EPTB and ATT were collected. CD4 counts before initiating ATT and after completion of ATT was collected. So, the prevalence rate of tuberculosis in HIV infected patients was found to be 6.7%. Out of 80 patients, 47 patients had extra pulmonary tuberculosis and 33 had pulmonary tuberculosis. Mean CD4 counts in patients with PTB prior to ATT was 241 cells/ μ l ranging from (22-541 cells/ μ l). Mean CD4 counts in patients with EPTB prior to ATT was 224 cells/ μ l, ranging from (80-600 cells/ μ l). Following ATT, it was 322 cells/ μ l in PTB patients and 303 cells/ μ l in EPTB patients. There was statistically significant increase in CD4 count after ATT in PTB and EPTB.

Keywords: HIV, PTB, EPTB, CD4 counts, ART, ATT.

INTRODUCTION

Tuberculosis is a common opportunistic infection and a leading cause of death in HIV patients worldwide, especially in developing countries [1]. There are clinical and experimental evidences suggesting that active TB accelerate the course of HIV disease [1]. HIV infection being an immunosuppressive disease predisposes patient with latent tuberculosis infection to develop tuberculosis disease². In addition, immunosuppression also leads to reactivation of old tuberculosis infection and to previously treated patient being easily re-infected when exposed to a patient with the disease [2]. TB provides a milieu of continuous cellular activation and irregularities in cytokine and chemokine circuits that are permissive of HIV replication [3]. In tuberculosis-HIV co-infection, the clinical features of tuberculosis are altered due to immunosuppression [2]. Estimation of CD4 T-lymphocyte is one of the measures of ascertaining the immune competence of the HIV infected individual. We hypothesized that since TB infection contributes to additional reduction in CD 4counts in HIV/TB patients, there would be greater improvement in CD4 counts following treatment with ATT and ART. Main aim of the study was to evaluate the relation of CD4 counts to

occurrence and type of TB and to observe for the recovery of CD4 counts after treatment for tuberculosis in patients of pulmonary tuberculosis and extra pulmonary tuberculosis.

MATERIALS AND METHODS

This retrospective study was conducted for a period of 2 months (February 2015- March 2015) at Dr. Ram Manohar Lohia Hospital & PGIMER. Total Number of HIV positive patients that came for CD4 testing were 1187. 80 patients who had dual infection (HIV with tuberculosis) were included in the study. Details regarding age, sex, duration of HIV, ART therapy, type of tuberculosis whether PTB (Pulmonary tuberculosis) or EPTB (Extrapulmonary tuberculosis) and ATT were collected. CD4 counts before initiating ATT and after completion of ATT was collected. HIV seropositivity was diagnosed by using NACO approved SD bioline, CombaIDS and trispot test kits interpreted as per manufacturer instruction and diagnosis was done as per national guidelines. CD4 count was performed by FACS Calibur. Collected data was statistically analysed with SPSS software for windows, version 20.0.

RESULTS AND DISCUSSION

In this study we included 1187 HIV positive patients who came for CD4 testing. Out of 1187, 80 patients had dual infection (HIV with tuberculosis). So, the prevalence rate of tuberculosis in HIV infected patients was found to be 6.7%. Out of 80 patients, 47 patients had pulmonary tuberculosis and 33 had extra pulmonary tuberculosis (Table 1). Out of 47 patients of PTB, 40 were male and 7 were female while among 33 EPTB patients 25 were male and 8 were female.

Among the type of EPTB analyzed abdominal tuberculosis was the commonest form of EPTB found, followed by tubercular lymphadenitis, tuberculosis

meningitis and spinal tuberculosis. The distribution is shown in table 2.

Mean CD4 counts in patients with PTB prior to ATT was 241 cells/ μ l ranging from (22-541 cells/ μ l). Mean CD4 counts in patients with EPTB prior to ATT was 224 cells/ μ l, ranging from (80-600 cells/ μ l). Following ATT, it was 322 cells/ μ l in PTB patients and 303 cells/ μ l in EPTB patients.(Table 3). Incidence of both EPTB and PTB was higher in age group of 31-40 years. Age wise distribution of the disease and respective CD4 counts are shown in Table 4. There was statistically significant difference in CD4 count before and after ATT in PTB (p value = .000) and EPTB (p value = .006).

Table-1: Distribution of cases of tuberculosis

Tuberculosis	Frequency	Percent
PTB	47	58.8
EPTB	33	41.2
Total	80	100

Table-2: Distribution of cases of EPTB and their incidence

Extrapulmonary Tuberculosis	Number of cases	Percent
Tubercular abdomen	16	48.5
Tubercular lymphadenitis	10	30.3
Tubercular meningitis	4	12.1
Spine tuberculosis	3	9.0
Total	33	100

Table-3: CD4 counts before and after ATT

	Tuberculosis	Mean
CD4 count before ATT (cells/ μ l)	PTB	241
	EPTB	224
CD4 count after ATT (cells/ μ l)	PTB	322
	EPTB	303

Table-4. CD4 counts in different age groups

Age (years)	Tuberculosis	Number of patients	Mean CD4 count before ATT(cells/ μ l)	Mean CD4 count after ATT(cells/ μ l)
11-20	PTB	4	276	418
	EPTB	0	0	0
21-30	PTB	7	220	373
	EPTB	6	327	374
31-40	PTB	18	273	322
	EPTB	16	187	302
41-50	PTB	14	212	281
	EPTB	9	231	297
51-60	PTB	2	115	153
	EPTB	1	147	101
61-70	PTB	2	376	424
	EPTB	1	105	170

Tuberculosis is the most common opportunistic infection in HIV patients in India [4]. In our study we found that 41.2 % of study population had PTB while 58.8% of study population had EPTB. Magnitude of CD4 cell recovery may depend on variety of factors including maintenance of virological suppression with ART, age and CD4 count at ART initiation [5]. In this retrospective study we compared the change in CD4 counts following ATT and ART in HIV and tuberculosis infected patients.

Additional increment in CD4 counts in patient with co-infection following treatment suggest that CD4 suppression at the onset of TB maybe the direct evidence of Mycobacterium tuberculosis growth¹. Interaction between TB and HIV have additional effect on CD4 counts as compared to HIV alone [1]. CD4 lymphocyte depletion is known to occur in TB patients not affected with HIV⁶ and become normal following ATT [7].

Mean CD4 count before and after ATT in HIV and EPTB patients was lower when compared with HIV and PTB patients.(Table 3)Mean CD4 count in EPTB was lower than in case of PTB. There was a statistically significant recovery in CD4 counts following ATT and ART. Similar results were reported in other studies. In a study conducted by Kavya et al there was a significant increase in CD4 counts before and after ATT & ART in PTB and EPTB [8]. In other study by Wanchu et al there was a greater increment in CD4 counts with ATT and ART in dually infected patients [1]. In the study by Elliott AM, et al. in HIV patients with pleural TB, CD4 count improved following ATT but did not reach statistical significance [9]. In South African patients with dual infection not receiving ART, median CD4 count improved from 186 cells/mm³ at baseline to 239 cells/mm³ after 6 months of ATT but the change was not statistically significant [10]. In the prospective study by Kalou M, et al. CD4 count changed from 393 cells/mm³ at baseline to 370 cells/mm³ at 12 months of follow-up [11]. Significant increase in CD4 counts during treatment for tuberculosis strongly suggests that TB additionally contributes to subnormal CD4 levels in blood.

In HIV patients affected with TB, TB adds to the immunologic deterioration caused by HIV [1]. Patients with co-infection show elevated levels of pro inflammatory cytokines and increased expression of cellular activation markers [12]. ATT results in decrease level of some of these markers of immune activation and consequently rise in CD4 cell count is expected [13].Our study has few limitations like we did not have data on viral load in our patients as routine viral load testing is not available. Even with this limitation our study provides some evidence in the clinical setting that TB additionally influences the reduction in CD4 count in HIV patients.

CONCLUSION

There was statistically significant increase in CD4 count after ATT in PTB and EPTB. Greater increment in CD4 counts with ATT and ART in dually infected patients suggests that TB additionally influences the reduction of CD4 counts in HIV patients.

REFERENCES

1. Wanchu A, Kuttiatt VS, Sharma A, Singh S, Varma S; CD4 cell count recovery in HIV/TB co-infected patients versus TB uninfected HIV patients. *Indian J Pathol Microbiol* 2010; 53(4): 745-749
2. Nwabuko CO, Ejele OA, Chuku A, Nnoli MA, Chukwuonye II; Prevalence of Tuberculosis-HIV Coinfection and Relationship between Tuberculosis and CD4/ESR in HIV Patients in Niger Delta Region of Nigeria. *J. Dent.Med.* 2(4):1-4.
3. Toossi Z; Virological and immunological impact of tuberculosis on human Immunodeficiency virus type 1 disease. *J Infect Dis*, 2003; 188(8): 1146-1155.
4. Kumarasamy N, Solomon S, Flanigan TP, Hemalatha R, Thyagarajan SP, Mayer KH; Natural history of human immunodeficiency virus disease in southern India. *Clin Inf Dis*, 2003; 36(1): 79-85.
5. Lifson AR, Krantz EM, Eberly LE, Matthew Dolan J, Marconi VC, Weintrob AC; Long-term CD4+ lymphocyte response following HAART initiation in a U.S. Military prospective Cohort. *AIDS Res Ther* 2011, 8(1): 2.
6. Onwubalili JK, Edwards AJ, Palmer L; T4 lymphopenia in human tuberculosis. *Tubercle*, 1987; 68(3): 195-200.
7. Jones BE, Oo MM, Taikwel EK, Qian D, Kumar A, Maslow ER, Barnes PF; CD4 cell counts in human immunodeficiency virus—negative patients with tuberculosis. *Clinical Infectious Diseases*, 1997; 24(5): 988-991.
8. Kavya S, Anuradha K, Venkatesha D; CD4 count evaluation in HIV-TB co infection before and after anti-tubercular treatment. *International Journal of Research in Medical Sciences*, 2014; 2(3): 1031-1034.
9. Elliott AM, Luzze H, Quigley MA, Nakiyingi JS, Kyaligonza S, Namujju PB, Okwera A; A Randomized, Double-Blind, Placebo-Controlled Trial of the Use of Prednisolone as an Adjunct to Treatment in HIV-1—Associated Pleural Tuberculosis. *Journal of Infectious Diseases*, 2004; 190(5): 869-878.
10. Morris L, Martin DJ, Bredell H, Nyoka SN, Sacks L, Pendle S, Chaisson RE; Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. *Journal of Infectious Diseases*, 2003; 187(12): 1967-1971.

11. Kalou M, Sassan M, Abouya L, Gelestin B, Chantal M, Mathieu M, et al; Change in HIV RNA viral load, CD4 T cell counts and levels and cotrimoxazole prophylaxis among HIV infected tuberculosis patients in Abidjan, *Journal of Medical Virology*, 2005; 75: 202-208.
12. Wallis RS, Vjecha M, Amir-Tahmasseb M; Influence of tuberculosis on human immunodeficiency virus (HIV-1): enhanced cytokine expression and elevated beta 2 microglobulin in HIV-1 associated tuberculosis. *J Infect Dis*, 1993; 167(1): 43-48.
13. Lawn SD, Shattock RJ, Acheampong JW, Lal RB, Folks TM, Griffin GE, et al.; Sustained plasma TNF alpha and HIV-1 load despite resolution of other parameters of immune activation during treatment of tuberculosis in Africans. *AIDS*, 1999; 13(16): 2231-2237.